# Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

> **NCT06497387** · EARLY_PHASE1 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Lupus Nephritis
- IgG4-related Disease

## Interventions

- **BIOLOGICAL:** PRG-1801

## Key facts

- **NCT ID:** NCT06497387
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2027-07
- **Final completion:** 2028-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06497387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06497387, "Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06497387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*